SEC14L2

Summary

SEC14L2 (SEC14 like lipid binding 2, HGNC:10699) is a protein-coding gene on chromosome 22q12.2, encoding SEC14-like protein 2 (O76054). Carrier protein.

This gene encodes a cytosolic protein which belongs to a family of lipid-binding proteins including Sec14p, alpha-tocopherol transfer protein, and cellular retinol-binding protein. The encoded protein stimulates squalene monooxygenase which is a downstream enzyme in the cholesterol biosynthetic pathway. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene.

Source: NCBI Gene 23541 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 50 total
• MANE Select transcript: NM_012429

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10699
Approved symbol	SEC14L2
Name	SEC14 like lipid binding 2
Location	22q12.2
Locus type	gene with protein product
Status	Approved
Aliases	TAP, SPF, KIAA1186, KIAA1658, TAP1
Ensembl gene	ENSG00000100003
Ensembl biotype	protein_coding
OMIM	607558
Entrez	23541

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 7 protein_coding, 4 protein_coding_CDS_not_defined, 4 retained_intron, 2 nonsense_mediated_decay

ENST00000402592, ENST00000405717, ENST00000415072, ENST00000416523, ENST00000428195, ENST00000429917, ENST00000437022, ENST00000452649, ENST00000459728, ENST00000464335, ENST00000483116, ENST00000484486, ENST00000485482, ENST00000615189, ENST00000617837, ENST00000619483, ENST00000620251

RefSeq mRNA: 4 — MANE Select: NM_012429 NM_001204204, NM_001291932, NM_012429, NM_033382

CCDS: CCDS13876, CCDS46685, CCDS56228

Canonical transcript exons

ENST00000615189 — 12 exons

Exon	Start	End
ENSE00003462307	30415948	30416087
ENSE00003612747	30409426	30409486
ENSE00003638388	30416234	30416403
ENSE00003655660	30410596	30410679
ENSE00003688973	30409187	30409282
ENSE00003702644	30407415	30407603
ENSE00003707262	30399643	30399718
ENSE00003710623	30397018	30397170
ENSE00003710944	30407095	30407154
ENSE00003711319	30406342	30406385
ENSE00003740809	30422277	30425303
ENSE00003788454	30415759	30415865

Expression profiles

Bgee: expression breadth ubiquitous, 207 present calls, max score 96.90.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.9195 / max 265.8515, expressed in 1524 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191679	11.1537	1497
191678	0.4635	252
191681	0.1819	91
191680	0.1204	49

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	96.90	gold quality
lower esophagus mucosa	UBERON:0035834	93.22	gold quality
liver	UBERON:0002107	91.99	gold quality
right frontal lobe	UBERON:0002810	90.76	gold quality
prefrontal cortex	UBERON:0000451	90.53	gold quality
nucleus accumbens	UBERON:0001882	90.41	gold quality
amygdala	UBERON:0001876	89.88	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	89.83	gold quality
caudate nucleus	UBERON:0001873	89.53	gold quality
cingulate cortex	UBERON:0003027	89.53	gold quality
putamen	UBERON:0001874	89.34	gold quality
anterior cingulate cortex	UBERON:0009835	89.32	gold quality
pigmented layer of retina	UBERON:0001782	89.20	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.10	gold quality
esophagus mucosa	UBERON:0002469	87.75	gold quality
spinal cord	UBERON:0002240	87.18	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	87.11	gold quality
hypothalamus	UBERON:0001898	86.52	gold quality
frontal cortex	UBERON:0001870	86.49	gold quality
neocortex	UBERON:0001950	86.45	gold quality
telencephalon	UBERON:0001893	85.85	gold quality
forebrain	UBERON:0001890	85.28	gold quality
cerebral cortex	UBERON:0000956	84.88	gold quality
corpus epididymis	UBERON:0004359	84.76	gold quality
substantia nigra	UBERON:0002038	84.68	gold quality
central nervous system	UBERON:0001017	84.28	gold quality
brain	UBERON:0000955	84.19	gold quality
adenohypophysis	UBERON:0002196	84.17	gold quality
Ammon’s horn	UBERON:0001954	84.02	gold quality
sural nerve	UBERON:0015488	83.92	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.13
E-ENAD-17	no	744.15
E-CURD-10	no	434.73

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
PSMB9	Unknown

miRNA regulators (miRDB)

62 targeting SEC14L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-132-3P	99.73	70.56	1424
HSA-MIR-212-3P	99.73	70.65	1424
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-664A-3P	99.22	71.08	2696
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-4292	99.16	65.57	1767
HSA-MIR-6791-5P	99.16	65.92	1844
HSA-MIR-6734-3P	99.15	66.27	1627
HSA-MIR-4324	99.04	70.14	1569
HSA-MIR-4650-3P	99.01	68.39	1062
HSA-MIR-3142	98.88	66.09	529
HSA-MIR-1245B-5P	98.88	66.55	576
HSA-MIR-6760-5P	98.87	66.73	1515
HSA-MIR-4477A	98.83	69.75	2952

Literature-anchored findings (GeneRIF, showing 18)

• SPF has two domain topology, and the ligand binding cavity has a peculiar horseshoe-like shape (PMID:12429094)
• phosphorylation enhances its ability to stimulate microsomal squalene monooxygenase; phosphorylation may provide a means for the rapid short term modulation of cholesterol synthesis (PMID:12454003)
• Data report the three-dimensional crystal structure of human supernatant protein factor in complex with RRR-alpha-tocopherylquinone, the major physiological oxidation product of RRR-alpha-tocopherol, at a resolution of 1.95A. (PMID:12972248)
• Discusses cloning of rat SEC14-like protein 3 and mentions three human SPF-related genes, known as SEC14-like protein 1, 2 and 3. (PMID:15033454)
• TAP not only mediates vitamin E absorption to facilitate vitamin E antiproliferation effect in prostate cancer cells, but also functions like a tumor suppressor gene to control cancer cell viability through a non-vitamin E manner. (PMID:16267002)
• reduced expression of TAP was associated with the cell proliferation status of prostate cancer, adverse pathological parameters and the increased risk of recurrence (PMID:17334589)
• Genetic variation in TTPA and SEC14L2 is associated with serum alpha-tocopherol but does not have a direct effect on prostate cancer when vitamin E is administered. (PMID:19190344)
• These findings are consistent with alpha-tocopherol-associated protein acting as an antiproliferative factor in estrogen-receptor-positive luminal cells in normal/benign breast tissue (PMID:19305383)
• Fndings raise the possibility that TAP/Sec14L2 may serve as a tumor suppressor in breast carcinogenesis. (PMID:19909011)
• novel association between the rs737723 polymorphism (SEC14L2/TAP) and higher primary open-angle glaucoma risk (PMID:23401652)
• TAP expression was significantly correlated with Her2/neu receptor expression and breast cancer stage. (PMID:23411208)
• hTAP1 reduces the in vitro activity of the phosphatidylinositol-3-kinase gamma (PI3Kgamma) indicating the formation of a stalled/inactive hTAP1/PI3Kgamma heterodimer. (PMID:24983950)
• PI3Kgamma-induced VEGF expression was reduced when the human tocopherol-associated protein 1 (hTAP1/SEC14L2) was overexpressed suggesting formation of an inactive PI3Kgamma/hTAP1 heterodimer. (PMID:25290554)
• SEC14L2 enabled RNA replication of diverse HCV genotypes in several human hepatoma cell lines (PMID:26266980)
• Here, the authors report that the zebrafish/human phosphatidylinositol transfer protein Sec14l3/SEC14L2 act as GTPase proteins to transduce Wnt signals from Frizzled to phospholipase C (PLC). (PMID:28463110)
• SEC14L2, a lipid-binding protein, regulates HCV replication in culture with inter- and intra-genotype variations. (PMID:30472319)
• Discovering master regulators in hepatocellular carcinoma: one novel MR, SEC14L2 inhibits cancer cells. (PMID:31851620)
• TAP-ing into the cross-presentation secrets of dendritic cells. (PMID:37116384)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	sec14l7	ENSDARG00000099633
mus_musculus	Sec14l2	ENSMUSG00000003585
rattus_norvegicus	Sec14l2	ENSRNOG00000004672
drosophila_melanogaster	retm	FBGN0031814
drosophila_melanogaster	CG13893	FBGN0035146
caenorhabditis_elegans		WBGENE00007925
caenorhabditis_elegans		WBGENE00009241
caenorhabditis_elegans	ctg-1	WBGENE00010370
caenorhabditis_elegans		WBGENE00011962

Paralogs (6): SEC14L3 (ENSG00000100012), SEC14L5 (ENSG00000103184), SEC14L1 (ENSG00000129657), SEC14L4 (ENSG00000133488), TTPA (ENSG00000137561), SEC14L6 (ENSG00000214491)

Protein

Protein identifiers

SEC14-like protein 2 — O76054 (reviewed: O76054)

Alternative names: Alpha-tocopherol-associated protein, Squalene transfer protein, Supernatant protein factor

All UniProt accessions (7): O76054, B3KRD8, C9JTM4, C9JYY7, C9JZI9, F8WED8, F8WEE7

UniProt curated annotations — full annotation on UniProt →

Function. Carrier protein. Binds to some hydrophobic molecules and promotes their transfer between the different cellular sites. Binds with high affinity to alpha-tocopherol. Also binds with a weaker affinity to other tocopherols and to tocotrienols. May have a transcriptional activatory activity via its association with alpha-tocopherol. Probably recognizes and binds some squalene structure, suggesting that it may regulate cholesterol biosynthesis by increasing the transfer of squalene to a metabolic active pool in the cell.

Subunit / interactions. Monomer.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Widely expressed. Strong expression in liver, brain and prostate.

Isoforms (3)

UniProt ID	Names	Canonical?
O76054-1	1	yes
O76054-4	2
O76054-5	3

RefSeq proteins (4): NP_001191133, NP_001278861, NP_036561, NP_203740 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001251	CRAL-TRIO_dom	Domain
IPR009038	GOLD_dom	Domain
IPR011074	CRAL/TRIO_N_dom	Domain
IPR036273	CRAL/TRIO_N_dom_sf	Homologous_superfamily
IPR036598	GOLD_dom_sf	Homologous_superfamily
IPR036865	CRAL-TRIO_dom_sf	Homologous_superfamily
IPR051064

Pfam: PF00650, PF03765

UniProt features (50 total): helix 19, strand 15, turn 5, modified residue 4, domain 2, splice variant 2, chain 1, sequence conflict 1, sequence variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
4OMJ	X-RAY DIFFRACTION	1.6
4OMK	X-RAY DIFFRACTION	1.75
1OLM	X-RAY DIFFRACTION	1.95
1O6U	X-RAY DIFFRACTION	2.05

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O76054-F1	95.76	0.93

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 51, 253, 257, 393

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 630 (showing top): WALLACE_PROSTATE_CANCER_RACE_UP, BENPORATH_ES_WITH_H3K27ME3, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, REACTOME_ANTIGEN_PRESENTATION_FOLDING_ASSEMBLY_AND_PEPTIDE_LOADING_OF_CLASS_I_MHC, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, MODULE_45, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_ANTIGEN_PROCESSING_AND_PRESENTATION_OF_PEPTIDE_ANTIGEN, BROWNE_HCMV_INFECTION_12HR_UP, KEGG_ABC_TRANSPORTERS, NFKB_Q6, HINATA_NFKB_TARGETS_KERATINOCYTE_UP, GOBP_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CHOLESTEROL_BIOSYNTHETIC_PROCESS, BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS

GO Biological Process (2): regulation of cholesterol biosynthetic process (GO:0045540), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (3): phospholipid binding (GO:0005543), vitamin E binding (GO:0008431), lipid binding (GO:0008289)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), extracellular exosome (GO:0070062)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cholesterol biosynthetic process	1
regulation of cholesterol metabolic process	1
regulation of sterol biosynthetic process	1
regulation of alcohol biosynthetic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
lipid binding	1
vitamin binding	1
heterocyclic compound binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
extracellular vesicle	1

Protein interactions and networks

STRING

572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SEC14L2	PI4KA	P42356	528
SEC14L2	CD81	P18582	507
SEC14L2	CLDN1	O95832	497
SEC14L2	PPIA	P05092	470
SEC14L2	SCARB1	Q8WTV0	461
SEC14L2	DVL2	O14641	432
SEC14L2	APOE	P02649	415
SEC14L2	CD302	Q8IX05	379
SEC14L2	SQLE	Q14534	361
SEC14L2	CCDC74A	Q96AQ1	355
SEC14L2	SRFBP1	Q8NEF9	349
SEC14L2	CYP4F2	P78329	312
SEC14L2	CCDC74B	Q96LY2	308
SEC14L2	BUD13	Q9BRD0	307
SEC14L2	LPL	P06858	292

IntAct

5 interactions, top by confidence:

A	B	Type	Score
SEC14L3	SEC14L2	psi-mi:“MI:0914”(association)	0.530
SEC14L2	Ppm1l	psi-mi:“MI:0915”(physical association)	0.400
SPANXN2	ZNF320	psi-mi:“MI:0914”(association)	0.350

BioGRID (28): SEC14L2 (Affinity Capture-MS), SEC14L2 (Affinity Capture-RNA), SEC14L2 (Affinity Capture-RNA), SEC14L2 (Affinity Capture-MS), SEC14L2 (Affinity Capture-MS), SEC14L2 (Co-fractionation), SEC14L2 (Co-fractionation), GOT2 (Co-fractionation), CSTB (Co-fractionation), GPI (Co-fractionation), RAC2 (Co-fractionation), ANXA7 (Co-fractionation), ALDH4A1 (Co-fractionation), PEBP1 (Co-fractionation), S100A11 (Co-fractionation)

ESM2 similar proteins: A7T167, B3MZN7, B4PYH5, B5MCN3, F4JYJ3, O17907, O35239, O76054, P24280, P24859, P34913, P34914, P43378, P49193, P53989, P56523, P58875, P80299, Q03606, Q16KN5, Q16P87, Q29JQ0, Q2TAF8, Q4V8Q1, Q5RFR0, Q641Z2, Q653S9, Q6IPT4, Q6J756, Q6Q2C2, Q75DK1, Q78EJ9, Q8L7L1, Q8R0F9, Q91VA3, Q99J08, Q99MS0, Q9BTX7, Q9D3D0, Q9FKS0

Diamond homologs: A8Y5H7, B5MCN3, F4IHJ0, F4J7S8, F4JLE5, F4JVA6, F4JVA9, F4JYJ3, F4K6D3, O43304, O76054, P49193, P58875, Q03606, Q0V9N0, Q16KN5, Q29JQ0, Q7PWB1, Q8GXC6, Q8R0F9, Q92503, Q93ZE9, Q94A34, Q99J08, Q99MS0, Q9SI13, Q9SIW3, Q9UDX3, Q9UDX4, Q9VMD6, Q9Z1J8, Q10137, F4HP88, P24280, P24859, P33324, P45816, P46250, P53989, Q501H5

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
PKA	“up-regulates activity”	SEC14L2	phosphorylation
PRKACA	“up-regulates activity”	SEC14L2	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

50 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

3289 predictions. Top by Δscore:

Variant	Effect	Δscore
22:30397168:AAGG:A	donor_loss	1.0000
22:30397169:AGGTG:A	donor_loss	1.0000
22:30397170:GGT:G	donor_loss	1.0000
22:30397171:GTGAG:G	donor_loss	1.0000
22:30397172:T:A	donor_loss	1.0000
22:30399641:A:AG	acceptor_gain	1.0000
22:30399642:G:GG	acceptor_gain	1.0000
22:30399725:G:T	donor_gain	1.0000
22:30406340:A:AG	acceptor_gain	1.0000
22:30406341:G:GG	acceptor_gain	1.0000
22:30406384:AGGT:A	donor_loss	1.0000
22:30406386:GTGAG:G	donor_loss	1.0000
22:30406387:T:G	donor_loss	1.0000
22:30407093:A:AG	acceptor_gain	1.0000
22:30407094:G:GG	acceptor_gain	1.0000
22:30407094:GCAT:G	acceptor_gain	1.0000
22:30407413:A:AG	acceptor_gain	1.0000
22:30407413:AG:A	acceptor_gain	1.0000
22:30407413:AGGT:A	acceptor_gain	1.0000
22:30407414:G:A	acceptor_loss	1.0000
22:30407414:G:GG	acceptor_gain	1.0000
22:30407414:GG:G	acceptor_gain	1.0000
22:30407414:GGT:G	acceptor_gain	1.0000
22:30407414:GGTG:G	acceptor_gain	1.0000
22:30407414:GGTGA:G	acceptor_gain	1.0000
22:30407599:CAAAG:C	donor_gain	1.0000
22:30407600:AAAG:A	donor_gain	1.0000
22:30407601:AAG:A	donor_gain	1.0000
22:30407601:AAGGT:A	donor_loss	1.0000
22:30407602:AG:A	donor_gain	1.0000

AlphaMissense

2655 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:30410617:C:A	A201D	0.999
22:30416235:T:A	W305R	0.999
22:30416235:T:C	W305R	0.999
22:30416242:T:C	F307S	0.999
22:30422289:T:C	F365S	0.999
22:30422296:C:A	N367K	0.999
22:30422296:C:G	N367K	0.999
22:30399709:T:A	W41R	0.998
22:30399709:T:C	W41R	0.998
22:30407473:T:A	V98D	0.998
22:30410626:T:C	L204P	0.998
22:30416084:T:A	L303H	0.998
22:30416084:T:C	L303P	0.998
22:30416271:G:T	G317W	0.998
22:30416272:G:A	G317E	0.998
22:30416320:T:C	M333T	0.998
22:30416387:C:G	C355W	0.998
22:30422280:T:A	V362D	0.998
22:30422286:G:C	R364P	0.998
22:30422303:A:C	S370R	0.998
22:30422305:C:A	S370R	0.998
22:30422305:C:G	S370R	0.998
22:30422320:G:C	K375N	0.998
22:30422320:G:T	K375N	0.998
22:30422325:T:A	V377D	0.998
22:30407508:G:C	G110R	0.997
22:30409253:T:A	W164R	0.997
22:30409253:T:C	W164R	0.997
22:30409478:T:A	V191D	0.997
22:30410614:T:A	V200E	0.997

dbSNP variants (sampled 300 via entrez): RS1000135396 (22:30414019 C>T), RS1000235419 (22:30397460 C>CA), RS1000241369 (22:30421813 C>G), RS1000696529 (22:30424827 G>T), RS1000726765 (22:30397071 C>A,T), RS1000744980 (22:30401523 AT>A,ATT), RS1000783329 (22:30408428 CA>C,CAA), RS1000943325 (22:30410043 T>C), RS1000964699 (22:30408050 C>T), RS1001175892 (22:30402851 G>A), RS1001206675 (22:30413939 A>G), RS1001231908 (22:30396868 C>T), RS1001394522 (22:30395430 A>G), RS1001445670 (22:30399845 C>G), RS1001498220 (22:30396792 A>G)

Disease associations

OMIM: gene MIM:607558 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001585_24	Breast size	4.000000e-07
GCST004607_193	Plateletcrit	7.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2071543	PSMB8, TAP1, TAP2		0.00	0
rs1135216	TAP1		0.00	0

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases expression, increases methylation	3
Valproic Acid	affects cotreatment, decreases expression, increases expression	3
Estradiol	affects cotreatment, increases expression	2
Smoke	increases abundance, decreases expression	2
Testosterone	increases expression, affects cotreatment, decreases reaction	2
Tobacco Smoke Pollution	affects expression, increases expression	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
pirinixic acid	increases activity, affects binding, decreases expression	1
bisphenol A	decreases expression	1
terbufos	affects response to substance	1
alpha-terpineol	decreases reaction, increases expression	1
sodium arsenite	decreases expression	1
linalool	decreases reaction, increases expression	1
gamma-terpinene	increases expression, decreases reaction	1
potassium chromate(VI)	decreases expression	1
terpinenol-4	decreases reaction, increases expression	1
lavender oil	decreases reaction, increases expression	1
di-n-butylphosphoric acid	affects expression	1
linalyl acetate	increases expression, decreases reaction	1
perfluoro-n-nonanoic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
Limonene	decreases reaction, increases expression	1
Eucalyptol	decreases reaction, increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Calcitriol	increases expression, affects cotreatment	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.